Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
NVO
Novo Nordisk A/S Com
$71.50
Chart
$58.33 (+22.58%)
$87.17 (-17.98%)
$81.1 (-11.84%)
$142.5 (-49.82%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
NVO
Novo Nordisk A/S Com
Current Price
$71.50
Login to view Novo Nordisk A/S Com (NVO) recommendation from the last 90 days from financial news and social media.
Chart
$58.33 (+22.58%)
$87.17 (-17.98%)
$81.1 (-11.84%)
$142.5 (-49.82%)
NVO Latest Headlines
Novo Nordisks High Risk/Reward Proposition: 129% Rally Or 65% Drop?. Novo Nordisk A/S (On May 12 2025 Novo Nordisk (
Fri May 23, 2025
Novo Nordisks High Risk/Reward Proposition: 129% Rally Or 65% Drop?. Novo Nordisk A/S (On May 12 2025 Novo Nordisk (
Fri May 23, 2025
Novo Nordisks High Risk/Reward Proposition: 129% Rally Or 65% Drop?. Novo Nordisk A/S (On May 12 2025 Novo Nordisk (
Fri May 23, 2025
Novo Nordisks High Risk/Reward Proposition: 129% Rally Or 65% Drop?. Novo Nordisk A/S (On May 12 2025 Novo Nordisk (
Fri May 23, 2025
Novo Nordisks former chief makes comeback to steer choice of new CEO.
Thu May 22, 2025
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs. Cignas pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.
Wed May 21, 2025
Novo Nordisk Foundation enters into strategic framework agreement with the World Health Organization (WHO) to advance global health. At the 78th World Health Assembly in The Foundation and WHO are deepening the partnership adopting a more strategic approach through the signature of a framework agreement that will enable the two organisations to accelerate progress by working together.This includes opportunities to collaborate on the promotion provision and ...
Wed May 21, 2025
Novo Nordisk Foundation enters into strategic framework agreement with the World Health Organization (WHO) to advance global health. At the 78th World Health Assembly in The Foundation and WHO are deepening the partnership adopting a more strategic approach through the signature of a framework agreement that will enable the two organisations to accelerate progress by working together.This includes opportunities to collaborate on the promotion provision and ...
Wed May 21, 2025
Novo Nordisk Shares Dip 3% on Sudden CEO Transition Announcement. NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.
Mon May 19, 2025
Novo Nordisk upgraded to AA from AA- by S&P Global Ratings.
Mon May 19, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
